MedTrace Logo

A Trial of Academic Detailing to Promote Prescribing of Biosimilars

NCT07221890 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1325

Last updated 2026-05-14

No results posted yet for this study

Summary

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are:

1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab?
2. Do in-person or virtual visits work better?

Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version.

Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Conditions

  • Autoimmune Diseases
  • Rheumatoid Arthritis (RA)
  • Inflammatory Bowel Disease (IBD)
  • Psoriasis (PsO)

Interventions

OTHER

Offered an academic detailing session

Clinicians will be offered an academic detailing session that will be delivered by a specially trained pharmacist, nurse, or physician (i.e., detailer). These academic detailers will be provided and trained by an independent non-profit organization. After a clinician agrees to participate in an academic detailing session, the detailer will schedule a 1-on-1 meeting lasting 15-20 minutes during which the detailer will provide educational information about biosimilars tailored to their knowledge and attitudes on the topic. During the session, the clinician will be provided printed and/or digital materials, including an educational brochure and patient education materials. Clinicians will also receive access to a summary evidence document containing all of the material with citations. Clinicians will also be offered the opportunity to claim continuing medical education (CME) credits for participating.

OTHER

Standard-of-care outreach from the insurance plan

Clinicians will receive formulary information from Humana to provide information about coverage of adalimumab (Humira) and its biosimilars.

Sponsors & Collaborators

  • Humana Healthcare Research, Inc.

    collaborator UNKNOWN

  • Brigham and Women's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-06
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07221890 on ClinicalTrials.gov